Clinical research
The new year began with a fairly low level of clinical trial news. Here’s a look.
News, much of it good, keeps coming in about the efficacy of the various COVID-19 vaccines. Here’s a look.
Frank Nestle, Sanofi’s chief scientific officer and Global Head of Research, and Dietmar Berger, Sanofi’s chief medical officer and Global Head of Development, provided an overview of the company’s clinical activities and highlighted some assets that will be key revenue drives for the company.
This morning, Alnylam announced vutrisiran met primary and all secondary endpoints. Here’s everything you need to know about the drug and its purpose.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
2021 is off to a hopeful start for some companies, executives and scientists, while others are forced to fold programs and recalibrate.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 5, 2021.
Calithera Biosciences reported that its CANTATA clinical trial of telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC) failed to hit the primary endpoint.
It’s not particularly surprising that there wasn’t a lot of clinical trial news between Christmas and New Year’s, although there was some. Here’s a look.
Axsome Therapeutics reported positive data from the long-term, open-label Phase III MOVEMENT trial of AXS-07 for the treatment of acute migraine.
PRESS RELEASES